(2006028062)

26.04.06

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2005 (12.05.2005)

PCT

(10) International Publication Number
WO 2005/042574 A1

(51) International Patent Classification[7]: C07K 14/47, G01N 33/50, C12N 15/10, C12Q 1/68

(21) International Application Number: PCT/US2004/036595

(22) International Filing Date: 2 November 2004 (02.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/517,143 3 November 2003 (03.11.2003) US

(71) Applicant *(for all designated States except US)*: **ACADIA PHARMACEUTICALS INC.** [US/US]; 3911 Sorrento Valley Road, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BURSTEIN, Ethan S.** [US/US]; 4168 Sturgeon Court, San Diego, CA 92130 (US). **PIU, Fabrice** [FR/US]; 11859 Stonedale Court, San Diego, CA 92131 (US). **MA, Jian-Nong** [CN/US]; 3911 Sorrento Valley Boulevard, San Diego, CA 92121 (US). **WEISSMAN, Jacques, Thomas** [US/US]; 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008 (US). **WEINER, David, M.** [US/US]; 4915 Muir Avenue, San Diego, CA 92107 (US). **SCULLY, Audra, L.** [US/US]; 1469 Sapphire Drive, Carlsbad, CA 92009 (US). **NASH, Norman** [CA/US]; 10495 Abalone Landing Terrace, San Diego, CA 92130 (US). **SPALDING, Tracy** [GB/US]; 4168 Sturgeon Court, San Diego, CA 92130 (US). **CURRIER, Erika** [US/US]; 877 Island Avenue, #106, San Diego, CA 92101 (US).

(74) Agent: **HART, Daniel**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



162162



ACTION

WO 2005/042574 A1

(54) Title: HIGH TROUGHPUT FUNCTIONAL ASSAY FOR G-PROTEIN COUPLED RECEPTORS USING A RAP-RAS CHIMERIC PROTEIN

(57) Abstract: Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conjuction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.